Experiment 838653
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV INFUSION |
| Organism | Empty organism |
| Citation | CAILLE,P: MONDESIR,JM: DROZ,JP: KERBRAT,P: GOODMAN,A: DUCRET,JP: THEODORE,C: SPIELMAN,M: ROUESSE,J: AMIEL,JL:. (1985). PHASE II TRIAL OF ELLIPTINIUM IN ADVANCED RENAL CELL CARCINOMA.. 69(7/8) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN THIS PHASE II TRIAL, 40 PATIENTS WITH ADVANCED RENAL CARCINOMA WERE TREATED WEEKLY BY 1 H INFUSION. OF 38 EVALUABLE FOR RESPONSE, THERE WERE 5 OBJECTIVE RESPONSES (13.2%). AVERAGE DURATION OF RESPONSE WAS 8 MONTHS (RANGE OF 5-11 MONTHS). DOSE LIMITING TOXICITY WAS THE INDUCTION OF ANTIELLIPTINIUM ANTIBODIES WHICH CAUSED INTRAVASCULAR HEMOLYSIS IN 3 PATIENTS.MYELOSUPPRESSION WAS NOT SEEN.NONHEMOTOLOGICAL TOXICITIES INCLUDE PHLEBITIS XEROSTOMIA,FEVER,CHILLS,NAUSEA,AND MUSCLE CRAMPS. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | EQUIVOCAL |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |